Corin, the manufacturer of replacement hip and knee joints, says it has seen growth in all its markets except Australia and describes the start of the year as 'strong'.
Looking at the numbers you can see where its coming from: for the four months ended April 30th, constant currency sales growth was 10% excluding stocking orders.
The growth has been led by sales of new hip products. Knee sales, which have in recent years declined, were broadly flat while ligament reconstruction products have shown good growth in the UK, but have in aggregate declined on the back of weaker Australian sales.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
There has been double-digit sales growth in the UK, US, Japanese and German and Austrian markets, with only the Australian business declining compared to the prior year.
Initial implantations of the new "Unity Knee" have gone well and the product remains on track for commercial launch early in 2013.
Corin shares had risen 5.5% by 10:45.
BS
-
UK-US trade deal announced: US cuts tariffs on UK car imports to 10%Keir Starmer and Donald Trump have announced a UK-US trade deal, but the US president has refused to lift baseline tariffs on most UK goods. What does it mean for the UK?
-
How to use mid-caps to diversify from the USMedium sized companies are overlooked by investors but could offer an attractive ‘sweet spot’. We consider the case for mid-caps amid market volatility.
